Retatrutide Cost: What to Expect When (and If) It's Approved

The content on this page is for general informational and educational purposes only and is not intended as medical advice, a recommendation, or an endorsement of any specific medication, treatment, or health product. Always consult a qualified healthcare provider before making decisions about medications, supplements, or changes to your health regimen. BodySpec does not prescribe, dispense, promote, offer, sell, or facilitate access to any of the pharmaceutical products discussed below.

Quick Summary

How much will retatrutide cost?
Retatrutide is an investigational drug currently in phase-3 clinical trials. It is not FDA-approved and does not have an official retail price. Based on the pricing of comparable FDA-approved GLP-1 medications, analysts estimate a projected retail cost of approximately $1,100–$1,400 per month before insurance if and when it reaches market.

What Is Retatrutide?

Retatrutide (LY3437943) is an investigational injectable developed by Eli Lilly that activates three metabolic receptors—GLP-1, GIP, and glucagon. In a phase-2 study, the highest dose produced an average 24% body-weight reduction over 48 weeks. The drug is currently in phase-3 clinical trials and is not FDA-approved. It is not legally available by prescription outside of clinical trials.

Projected Retail Pricing

Since Eli Lilly has not set a retail price, projected costs are based on the pricing of comparable FDA-approved medications in the same class:

• Zepbound (tirzepatide): approximately $1,060/month (Eli Lilly, 2024)
• Wegovy (semaglutide 2.4 mg): approximately $1,350/month (Novo Nordisk, 2024)

Based on these comparators, analysts expect retatrutide to launch in the $1,100–$1,400 per month range if approved, though the final price will depend on Eli Lilly's market strategy, the competitive landscape at the time of launch, and any negotiated payer agreements.

Clinical Trial Access

Participants enrolled in retatrutide clinical trials receive the drug at no cost. Clinical trial participation is the only way to access retatrutide under medical supervision with verified drug quality and safety monitoring. Information about enrolling in clinical trials is available through ClinicalTrials.gov.

A Note on Unapproved Sources

Because retatrutide is not FDA-approved, there is no legally marketed version available at pharmacies. The FDA has warned against compounded or grey-market versions of unapproved GLP-1 drugs due to concerns about purity, sterility, dosing accuracy, and patient safety. Products sold as "research peptides" are labeled not for human consumption and lack FDA oversight.

Insurance Coverage Outlook

Insurance coverage for retatrutide will depend on FDA approval and the specific indication:

• Commercial insurance: If approved for obesity (BMI ≥ 30, or ≥ 27 with comorbidities), coverage patterns would likely follow the trajectory of tirzepatide (Zepbound), which has seen increasing but uneven commercial coverage.
• Medicare: Federal law currently prohibits Medicare from covering weight-loss medications (KFF, 2024), though legislative efforts to change this are ongoing.
• Manufacturer savings programs: Eli Lilly has offered savings card programs for other branded medications (such as Zepbound), and a similar program for retatrutide is possible if the drug receives FDA approval.

These are projections based on current trends and are subject to change.

Frequently Asked Questions

When will retatrutide be available?
Retatrutide is in phase-3 clinical trials. If trials are successful, FDA review and potential approval could follow, but no specific timeline has been confirmed by Eli Lilly or the FDA.

Will retatrutide be cheaper than Wegovy or Zepbound?
This is unknown. Pricing will depend on Eli Lilly's strategy, the competitive landscape, and payer negotiations at the time of launch. The comparator pricing discussed above provides a reasonable range of estimates.

Is retatrutide the same as tirzepatide?
No. Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist. Retatrutide adds a third mechanism (glucagon receptor activation). They are different molecules developed by the same manufacturer.

The BodySpec Take

Retatrutide is an investigational triple-agonist medication with notable phase-2 clinical data, but it is not FDA-approved and is not available by prescription outside of clinical trials. Projected retail pricing is based on comparable FDA-approved medications and may change. All decisions about medications—including whether to participate in clinical trials—should be made with a qualified healthcare provider.

Regardless of what approach you and your healthcare provider choose, objective body composition data can help you understand what's changing over time. A DEXA scan measures fat mass, lean mass, visceral fat, and bone density—providing context that a scale alone cannot.

Book a BodySpec DEXA scan to track changes in lean mass, fat mass, and visceral fat.

Educational content only; not medical or legal advice. BodySpec does not diagnose, treat, prescribe, or sell medications.